Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
Completed
GlaxoSmithKline
Phase 3
2003-06-01
The purpose of this study is to compare the safety and effectiveness of as needed versus
fixed dosing of an investigational medication for women with severe diarrhea-predominant
Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
Completed
GlaxoSmithKline
Phase 3
2003-06-01
The purpose of this study is to compare the safety and effectiveness of different doses of an
investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome
(IBS) who have failed conventional therapy.
Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)
Completed
Hadassah Medical Organization
Phase 1
2005-07-01
This is an 8-week double-blind, placebo-controlled, randomized, parallel-group study with an
additional two week baseline observation period to evaluate the safety of combination herbal
therapy (CHT) versus placebo and short and long-term efficacy in terms of improved IBS,
overall quality of life (QOL) and symptomatology.
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
Completed
GlaxoSmithKline
Phase 4
2006-12-01
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs
placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
patients.
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
Completed
GlaxoSmithKline
Phase 2
2003-09-18
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in
Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and
(ii) to obtain reference data for endpoints and dosage and administration of a next phase
study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
